Search clinical trials for: Folfiri/Cetuximab

Total 3293 results

Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Unknown

A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Reirradiation and Erbitux in the HNSCC

Head and Neck Cancer Squamous Cell

France
Rambam Health Care Campus
Merck KGaA, Darmstadt, Germany

Completed

Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab

Colorectal Cancer Metastatic

Israel
Vanderbilt University
National Cancer Institute (NCI)

Completed

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

Gastric Cancer | Precancerous Condition

United States
Merck KGaA, Darmstadt, Germany
Merck, S.L., Spain

Completed

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype (MUTEX)

Colorectal Neoplasms

Spain
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Merck KGaA, Darmstadt, Germany

Completed

Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Head and Neck Cancer

Korea, Republic of
Karolinska University Hospital

Unknown

Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET)

Squamous Cell Carcinoma of the Head and Neck

Denmark, Sweden
Eli Lilly and Company
Bristol-Myers Squibb

Completed

A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

Colorectal Neoplasms

United States
M.D. Anderson Cancer Center

Active, not recruiting

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
University Hospital, Toulouse

Completed

Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab (PK-rituximab)

Autoimmune Diseases | Renal Transplant

France
Amgen

Completed

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Carcinoma | Cancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Gastrointestinal Cancer | Oncology | Metastases
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck

Head and Neck Cancer

United States
University of Chicago
Celgene Corporation

Completed

Cetuximab and Lenalidomide in Head and Neck

Squamous Cell Carcinoma

United States
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb; National Cancer Institute (NCI); Southwest Oncology Group; Aptu...

Completed

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
Walter Reed Army Medical Center
National Cancer Institute (NCI)

Unknown

Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer

Colorectal Cancer

United States
University of Massachusetts, Worcester

Completed

A Trial of Chemo & Radiation Therapy for Pancreatic Cancer

Pancreatic Cancer
Spanish Cooperative Group for the Treatment of...
Sanofi

Completed

Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (POLAF)

Metastatic Colorectal Cancer

Spain
Liqiang Zhong

Unknown

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

Colorectal Neoplasms
Grupo Español de Tratamiento de Tumores de Cabeza...
Merck Sharp & Dohme LLC; Pivotal S.L.

Terminated

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy (EXTAX)

Head and Neck Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
National Cancer Institute, Naples

Active, not recruiting

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer (MITO CERV 2)

Cervical Cancer

Italy
Wolfgang Hilbe
Sanofi; Merck Sharp & Dohme LLC; TAKO - Tiroler Arbeitskreis Onkologie

Completed

Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)

Carcinoma, Non-small-cell Lung

Austria
Heidelberg University
Merck KGaA, Darmstadt, Germany

Unknown

Paclitaxel/Carboplatin With or Without Cetuximab in CUP (PACET-CUP)

Carcinoma | Neoplasms, Unknown Primary

Germany
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
Nantes University Hospital

Completed

Diffuse Large B Cell Lymphoma of the Adult: Randomization Between High Dose Chemotherapy With Rituximab and CHOP 14-Rituximab

Lymphoma, Large-Cell, Diffuse

France
University of Copenhagen
Rigshospitalet, Denmark

Completed

Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome

Fatigue | Keratoconjunctivitis Sicca | Primary Sjögren's Syndrome | Xerostomia | Hyposalivation

Denmark
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Grupo Espanol Multidisciplinario del Cancer Digestivo

Completed

Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab (POSIBA)

Colorectal Cancer

Spain
Rabin Medical Center

Unknown

Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

Liver Metastasis Colon Cancer

Israel
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
Fudan University

Unknown

Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment

Colorectal Neoplasms

China
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; National Cheng-Kung... and other collaborators

Completed

A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma

Oral Cancer

Taiwan
Celgene Corporation

Terminated

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

Colorectal Cancer

Australia, Belgium, Germany, Italy, Spain, Sweden
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Colorectal Cancer
Incyte Corporation

Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Solid Tumors

United States, France, Italy, Australia, Spain, Canada, Belgium
AIO-Studien-gGmbH
Universitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...

Recruiting

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)

Colorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized Cancer

Germany
Fudan University

Not yet recruiting

Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis

Colorectal Cancer | Liver Metastases | Cetuximab
The Netherlands Cancer Institute
Dutch Cancer Society

Withdrawn

Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC

Lung Cancer | Surgery | Circulating Tumor Cell

Netherlands
University of Campania "Luigi Vanvitelli"

Completed

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | RAS Wild Type

Italy
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) (CARACAS)

Squamous Cell Anal Carcinoma

Italy
Abramson Cancer Center of the University of Pennsylvania

Completed

MLN8237 in Head and Neck Cancer

Head and Neck Cancer

United States
Sorlandet Hospital HF
Merck KGaA, Darmstadt, Germany; Frontier Science & Technology Research Foundation...

Completed

Novel Treatment Option for Neuropathic Pain (NoTOPain)

Neuralgia | Complex Regional Pain Syndromes

Norway
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada
Medical University of Vienna

Unknown

Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Austria
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Grade 3a Follicular Lymphoma

United States
Sun Yat-sen University

Recruiting

Crisaborole Ointment for Skin Toxicity Induced by Cetuximab (COSTIC)

Metastatic Colorectal Cancer | Cetuximab | Skin Toxicity

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

Skin Squamous Cell Carcinoma | Metastatic Skin Cancer

United States
University College, London
Merck KGaA, Darmstadt, Germany

Active, not recruiting

EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer (EACH)

Head and Neck Cancer | Squamous Cell Carcinoma

United Kingdom

Search clinical trials for: Folfiri/Cetuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations